DCOY ▲ +28.9% - Decoy Therapeutics Inc.
$DCOY - Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics jumped 28.9% after announcing it is exploring a pan-filovirus therapeutic program under the FDA's Animal Rule pathway, which allows drug approval based on animal efficacy data when human trials are infeasible, and that the company is pursuing non-dilutive funding to support development. The combination of a potentially expedited regulatory route and external funding without shareholder dilution likely drove investor optimism about the program's prospects and financial runway.
22-SEP-2026 07:31 AM ET
Share this post
More filings for $DCOY
DCOY ▼ -1.9% - Decoy Therapeutics Inc.Sep 30, 2026DCOY ▼ -1.7% - Decoy Therapeutics Inc.Sep 29, 2026DCOY ▲ +42.6% - Decoy Therapeutics Inc.Sep 22, 2026DCOY ▲ +33.6% - Decoy Therapeutics Inc.Sep 22, 2026DCOY ▲ +33.2% - Decoy Therapeutics Inc.Sep 22, 2026DCOY - Decoy Therapeutics Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $DCOY filing history →💬 Comments
Loading comments…
Leave a comment
